12:00 AM
 | 
Sep 27, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Avandia rosiglitazone regulatory update

FDA and the European Medicines Agency (EMA) issued decisions last week based on cardiovascular safety concerns that would significantly restrict use of Avandia rosiglitazone in the U.S. and suspend the diabetes drug in the EU. FDA said Avandia will only be available to new patients who achieve inadequate glycemic control on other medications and are unable for medical reasons...

Read the full 275 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >